Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study | MicrobiomeTrials
Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2024-11-18Est. Completion: 2026-05-31
Enrollment target: 130 participants
Locations
Nanjing BenQ Hospital, Nanjing, Jiangsu, China
Jiangsu province hospital, Nanjing, Jiangsu, China
Xuzhou Central hospital, Xuzhou, Jiangsu, China
The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China
Other microbiome trials you might be interested in